3SBio Inc. TRSBF

Company Overview

3SBio Inc. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of biologic therapies and selected small‑molecule drugs. The company operates primarily within the biopharmaceuticals and biotechnology industries, with a concentration on therapeutic areas such as nephrology, oncology, autoimmune diseases, and inflammation. Its core revenue is driven by proprietary biologics, biosimilars, and licensed products sold mainly through hospital channels in China.

The company is best known for its leadership position in recombinant protein therapeutics in China, particularly erythropoietin (EPO) products and tumor necrosis factor (TNF) inhibitors. 3SBio was founded in 1993 and has evolved from a domestic biologics manufacturer into a vertically integrated biopharmaceutical group with in‑house R&D, biologics manufacturing capabilities, and a nationwide sales network. Over time, it expanded its portfolio through internal development and acquisitions, strengthening its position in China’s biologics market.